Free Trial
NASDAQ:GRTX

Galera Therapeutics 8/14/2023 Earnings Report

Galera Therapeutics logo
$0.02 0.00 (-3.69%)
As of 11:44 AM Eastern

Galera Therapeutics EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Galera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galera Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Galera Therapeutics' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Galera Therapeutics Earnings Headlines

Galera Therapeutics extends agreement deadline
Missed Nvidia? Trump’s Trade War Could Create a Bigger Winner
Missed out on Nvidia? Don’t worry — a bigger AI opportunity may be emerging right now, thanks to Trump’s newly announced tariffs. One under-the-radar U.S. semiconductor stock just gained a major edge over its foreign rivals. With demand poised to skyrocket, this chipmaker could be perfectly positioned to ride the next wave of AI growth. Shares are still flying low — but not for long.
See More Galera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galera Therapeutics and other key companies, straight to your email.

About Galera Therapeutics

Galera Therapeutics (NASDAQ:GRTX), a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

View Galera Therapeutics Profile

More Earnings Resources from MarketBeat